7 April 2022 - Bimekizumab is a humanised immunoglobulin G1 kappa monoclonal antibody. It has two identical antigen binding regions that bind and neutralise interleukin 17A, 17F and 17AF cytokines.

Bimekizumab (Bimzelx) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Read TGA prescription medicine decision summary for bimekizumab